“Spesolimab Increases the Percentage of Generalized Pustular Psoriasis (GPP) Patients With Clear Skin over Time As Measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 Trial”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s490. Accessed May 2, 2026. https://skin.dermsquared.com/skin/article/view/3136.